King's College London

Research portal

Emerging role of the KRAS-PDK1 axis in pancreatic cancer

Research output: Contribution to journalReview articlepeer-review

Standard

Emerging role of the KRAS-PDK1 axis in pancreatic cancer. / Ferro, Riccardo; Falasca, Marco.

In: World Journal of Gastroenterology, Vol. 20, No. 31, 21.08.2014, p. 10752-10757.

Research output: Contribution to journalReview articlepeer-review

Harvard

Ferro, R & Falasca, M 2014, 'Emerging role of the KRAS-PDK1 axis in pancreatic cancer', World Journal of Gastroenterology, vol. 20, no. 31, pp. 10752-10757. https://doi.org/10.3748/wjg.v20.i31.10752

APA

Ferro, R., & Falasca, M. (2014). Emerging role of the KRAS-PDK1 axis in pancreatic cancer. World Journal of Gastroenterology, 20(31), 10752-10757. https://doi.org/10.3748/wjg.v20.i31.10752

Vancouver

Ferro R, Falasca M. Emerging role of the KRAS-PDK1 axis in pancreatic cancer. World Journal of Gastroenterology. 2014 Aug 21;20(31):10752-10757. https://doi.org/10.3748/wjg.v20.i31.10752

Author

Ferro, Riccardo ; Falasca, Marco. / Emerging role of the KRAS-PDK1 axis in pancreatic cancer. In: World Journal of Gastroenterology. 2014 ; Vol. 20, No. 31. pp. 10752-10757.

Bibtex Download

@article{6d04f3d73d0e41d49711a0ec1099810a,
title = "Emerging role of the KRAS-PDK1 axis in pancreatic cancer",
abstract = "Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it has the grim supremacy in terms of unfavourable survival rates. There have been great advances in survival rates for many types of cancers over the past few decades but hardly any change for pancreatic cancer. Mutations of the Ras oncogene are the most frequent oncogenic alterations in human cancers. The frequency of KRAS mutations in pancreatic cancer is around 90%. Given the well-established role of KRAS in cancer it is not surprising that it is one of the most attractive targets for cancer therapy. Nevertheless, during the last thirty years all attempts to target directly KRAS protein have failed. Therefore, it is crucial to identify downstream KRAS effectors in order to develop specific drugs able to counteract activation of this pathway. Among the different signalling pathways activated by oncogenic KRAS, the phosphoinositide 3-Kinase (PI3K) pathway is emerging as one of the most critical KRAS effector. In turn, PI3K activates several parallel pathways making the identification of the precise effectors activated by KRAS/PI3K more difficult. Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumour-initiating event downstream KRAS interaction with PI3K in pancreatic cancer.",
keywords = "3-Phosphoinositide-Dependent Protein Kinases, MicroRNAs, Molecular Targeted Therapy, Mutation, Pancreatic Neoplasms, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Signal Transduction, ras Proteins",
author = "Riccardo Ferro and Marco Falasca",
year = "2014",
month = aug,
day = "21",
doi = "10.3748/wjg.v20.i31.10752",
language = "English",
volume = "20",
pages = "10752--10757",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "31",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Emerging role of the KRAS-PDK1 axis in pancreatic cancer

AU - Ferro, Riccardo

AU - Falasca, Marco

PY - 2014/8/21

Y1 - 2014/8/21

N2 - Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it has the grim supremacy in terms of unfavourable survival rates. There have been great advances in survival rates for many types of cancers over the past few decades but hardly any change for pancreatic cancer. Mutations of the Ras oncogene are the most frequent oncogenic alterations in human cancers. The frequency of KRAS mutations in pancreatic cancer is around 90%. Given the well-established role of KRAS in cancer it is not surprising that it is one of the most attractive targets for cancer therapy. Nevertheless, during the last thirty years all attempts to target directly KRAS protein have failed. Therefore, it is crucial to identify downstream KRAS effectors in order to develop specific drugs able to counteract activation of this pathway. Among the different signalling pathways activated by oncogenic KRAS, the phosphoinositide 3-Kinase (PI3K) pathway is emerging as one of the most critical KRAS effector. In turn, PI3K activates several parallel pathways making the identification of the precise effectors activated by KRAS/PI3K more difficult. Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumour-initiating event downstream KRAS interaction with PI3K in pancreatic cancer.

AB - Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it has the grim supremacy in terms of unfavourable survival rates. There have been great advances in survival rates for many types of cancers over the past few decades but hardly any change for pancreatic cancer. Mutations of the Ras oncogene are the most frequent oncogenic alterations in human cancers. The frequency of KRAS mutations in pancreatic cancer is around 90%. Given the well-established role of KRAS in cancer it is not surprising that it is one of the most attractive targets for cancer therapy. Nevertheless, during the last thirty years all attempts to target directly KRAS protein have failed. Therefore, it is crucial to identify downstream KRAS effectors in order to develop specific drugs able to counteract activation of this pathway. Among the different signalling pathways activated by oncogenic KRAS, the phosphoinositide 3-Kinase (PI3K) pathway is emerging as one of the most critical KRAS effector. In turn, PI3K activates several parallel pathways making the identification of the precise effectors activated by KRAS/PI3K more difficult. Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumour-initiating event downstream KRAS interaction with PI3K in pancreatic cancer.

KW - 3-Phosphoinositide-Dependent Protein Kinases

KW - MicroRNAs

KW - Molecular Targeted Therapy

KW - Mutation

KW - Pancreatic Neoplasms

KW - Phosphatidylinositol 3-Kinases

KW - Protein Kinase Inhibitors

KW - Proto-Oncogene Proteins

KW - Proto-Oncogene Proteins p21(ras)

KW - Signal Transduction

KW - ras Proteins

U2 - 10.3748/wjg.v20.i31.10752

DO - 10.3748/wjg.v20.i31.10752

M3 - Review article

C2 - 25152578

VL - 20

SP - 10752

EP - 10757

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 31

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454